Jerald Radich, MD; and Christopher S. Hourigan, MD, DPhil, FACP, FRCP; discuss minimal residual disease. Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022 Marina Konopleva, MD, PhD, discusses her new role at the Albert Einstein College of Medicine and highlights from her career ... We are entering the great era of immunotherapy in multiple myeloma, as we’ve had significant... International Chronic Myeloid Leukemia (CML) Day takes place on September 22. Guillermo Garcia-Manero, MD, gives his perspective. September is Blood Cancer Awareness Month. Advances have been accomplished in the management of adults with acute lymphoblastic leukemia... Pankit J. Vachhani, MD, and Srdan Verstovsek, MD, debate the usefulness of variant allele frequency (VAF). Peter M. Voorhees, MD, of the Levine Cancer Institute at Atrium Health, and Thomas Martin, MD, of the University of ... Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint. With increasing evidence of efficacy as front-line treatment in relapsed/refractory disease, clinicians are excited to see ... Welcome to the second issue of Blood Cancers Today, where we’re continuing to share stories and updates on data that ... Jeffrey Lancet, MD, of Moffitt Cancer Center, reflects on the mentorship that helped him through a career crossroads. Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts. Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO. Decades in the making, information on measurable residual disease can greatly affect therapeutic decision making in ALL. The pace of change in blood cancers is quite dramatic, and new paradigms of treatment, assessment, and pathogenesis occur ... Farhad Ravandi, MD, and Jeffrey Lancet, MD, squared off on this clinical quandary. Dr. Maddocks reflects on her small-town upbringing and learning to love triathlons.